Musk's Personal Account
Tech mogul Elon Musk recently voiced a personal experience with a COVID-19 vaccine, stating it was far more severe than contracting the original virus.
He shared on social media that his second vaccine dose left him feeling critically ill, almost necessitating hospitalization. Musk's sentiment was a response to another post that highlighted a former Pfizer toxicologist's assertions about vaccine-related fatalities in Germany, suggesting that the vaccine's dosage and frequency might have been excessive. This personal anecdote, shared with his vast online following, brought renewed attention to ongoing debates about vaccine side effects and their severity compared to the disease itself.
Toxicologist's Grave Concerns
The foundation for Musk's comment rests on statements made by Dr. Helmut Sterz, a former head of toxicology centers in Europe for Pfizer. During proceedings related to Germany's pandemic inquiry, Dr. Sterz expressed significant apprehension regarding the accelerated development and testing phases of Pfizer's Comirnaty mRNA vaccine. He specifically noted that crucial aspects like carcinogenic risks were not adequately investigated due to time constraints. Furthermore, Dr. Sterz lamented the lack of alternative research and raised concerns about the reliability of animal testing for assessing the vaccine's impact on pregnancy, pointing out that pre-approval studies were limited in scope. This expert testimony casts a shadow over the rigorousness of the approval process.
Regulatory Scrutiny and Data
Dr. Sterz's critique extended to Germany's Robert Koch Institute (RKI), suggesting a prioritization of speed over comprehensive evaluation during the pandemic response. He stated that essential toxicity studies were bypassed without sufficient justification, likening the approval process to prohibited human experimentation. Internal RKI communications apparently indicated that side effect monitoring was predominantly planned for post-vaccination rollout. Moreover, Dr. Sterz referred to early Pfizer data post-approval that documented over 1,200 suspected deaths within a short timeframe, arguing that the vaccine should have been withdrawn from the market then. The Paul Ehrlich Institute has reported over 2,000 deaths in Germany following vaccination, with Dr. Sterz postulating that underreporting could inflate the actual figure significantly, potentially reaching 60,000 deaths attributable to vaccination in Germany.
Manufacturing and Health Risks
Another significant point raised by Dr. Sterz involves discrepancies between the vaccine formulation used in clinical trials and the mass-produced version distributed to the public. He alleged that the commercially available vaccine contained bacterial components, such as Escherichia coli. This inclusion, according to Dr. Sterz, could lead to contamination with bacterial DNA and, consequently, pose a substantially elevated risk of cancer. This claim introduces a complex layer of concern regarding potential contaminants introduced during the large-scale manufacturing process and their long-term health implications, further fueling the debate on vaccine safety and oversight.
